We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThis study aimed to review timelines and use of financial agreements for products being appraised.
Read more... and the use of financial arrangements for new oncology and non-oncology drugs?
Read moreHow has the data available within NCRAS been utilized within the CDF overseen by NICE, in partnershi...
Read moreCAR T-cell therapies and speculation in the pricing and market access implications for the lymphoma ...
Read moreThis resolution includes proposed reforms to the market access (including pricing) landscape designe...
Read moreMaximising the cost-saving potential of biosimilars remains a topic of much interest to payers and p...
Read moreIn this study, we compared the use of financial agreements for oncology and non-oncology drugs asses...
Read moreIs the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...
Read moreThis study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...
Read more